Clinical Trials

YCAAD has been involved in a host of both industry and investigator sponsored trials.  Below is a list of the most recent studies patients at YCAAD have been part of. 

Open to enrollment

Active but closed to enrollment

  • Genentech --- An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)

Closed to accrual

  • GSK --- A multicentre, randomized, double blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma (MEA 112997)